Atrium Gets $15M in Latest Milestone Payment from Bristol Myers Squibb
Dow Jones
Aug 13
Atrium Therapeutics earned another $15 million milestone payment from Bristol Myers Squibb based on the successful delivery of a compound targeting an undisclosed cardiology indication.
The payment is pursuant to Atrium's global licensing-and-research partnership with BMS, the biopharmaceutical company, which focuses on RNA therapies for the heart, said Thursday.
Under the terms of the agreement, Atrium is eligible to receive up to $1.35 billion in research-and-development milestones payments, as well as up to $825 million in commercial milestone payments.
It is also eligible for royalties of up to a low double-digit percentage of net sales. BMS will fund all future clinical development, regulatory and commercial activities coming from the collaboration.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.